Agilent, Axion End Cell Analysis IP Suit After Jury Selection
By Editorial Team
Laboratory equipment company Agilent Technologies and biotechnology business Axion BioSystems have reached an agreement to settle their legal dispute involving allegations of patent infringement. The resolution came just before the trial was set to commence on Monday.
Agilent Technologies and Axion BioSystems were embroiled in litigation over intellectual property rights related to cell analysis technology. The lawsuit accused Axion BioSystems of infringing on Agilent's patents.
Both companies have decided to end the legal battle, bringing an end to the courtroom confrontation. The terms of the settlement agreement have not been disclosed to the public.
The case was pending in the U.S. District Court for the District of Delaware. The patents at the center of the dispute included:
- 7,192,752 - Real-time electronic cell sensing systems and applications for cell-based assays
- 7,468,255 - Method for assaying for natural killer, cytotoxic T-lymphocyte, and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
- 8,026,080 - Real-time electronic cell sensing system and applications for cell-based assays
The legal teams involved in the case included law firms such as Ashby & Geddes, Jones Day, Morris Nichols, and Reed Smith, representing the respective parties.
With the settlement reached, the dispute between Agilent Technologies and Axion BioSystems has come to a close, avoiding the need for a trial to proceed.